国际肿瘤学杂志

国际肿瘤学杂志››2014,Vol. 41››Issue (10): 760-763.doi:１０．３７６０／ｃｍａ．ｊ．ｉｓｓｎ．１６７３４２２Ｘ．２０１４．１０．０１３

• 综述 •上一篇下一篇

Ｈｅｒ２基因与乳腺癌靶向治疗

黄灵潇,姚文秀

  1. ４０００１６重庆医科大学临床学院
  • 出版日期:2014-10-29发布日期:2014-10-11
  • 通讯作者:姚文秀，Ｅｍａｉｌ：ｙｗｘｈｌｘ＠ｓｉｎａ．ｃｏｍ E-mail:ｙｗｘｈｌｘ＠ｓｉｎａ．ｃｏｍ

Her2 gene and breast cancer targeted therapy

HUANG Ling-Xiao, YAO Wen-Xiu

  1. Clinical College, Chongqing Medical University, Chongqing 400016, China
  • Online:2014-10-29Published:2014-10-11
  • Contact:ＹａｏＷｅｎｘｉｕ E-mail:ｙｗｘｈｌｘ＠ｓｉｎａ．ｃｏｍ

PDF

1271

摘要：近年来随着肿瘤分子生物学技术的发展，分子靶向药物治疗已成为众多学者关注的热点 领域，对乳腺癌的治疗策略产生了重大影响。其中，人表皮生长因子受体２（Ｈｅｒ２）已证实为一个有效 的分子靶向治疗的靶标，针对乳腺癌 Ｈｅｒ２的分子靶向治疗成为近来继化疗和内分泌治疗后又一重要 的治疗手段。

关键词:乳腺肿瘤,靶向治疗,Ｈｅｒ２基因

Abstract:In recent years, with the development of tumor molecular biology technology, molecular targeted therapy has become a study hotspot, which plays a significant role on breast cancer treatment strategy. Among them, the human epidermal growth factor receptor2 (Her2) has been proven as an effective molecular target. So molecular targeted therapy of breast cancer become another important treatment except chemotherapy and endocrine therapy.

Key words:Breast neoplasms,Targeted therapy,Her2 gene